Afamelanotide in protoporphyria and other skin diseases: a review

被引：1

作者：

Polanska, Adriana ^{[1
,3
]}

Wegner, Joanna ^{[2
]}

Nutbohm, Paula ^{[2
]}

Staubach, Petra ^{[2
]}

Zaba, Ryszard ^{[1
]}

Danczak-Pazdrowska, Aleksandra ^{[1
]}

Jenerowicz, Dorota ^{[1
]}

机构：

[1] Poznan Univ Med Sci, Dept Dermatol, Poznan, Poland

[2] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany

[3] Univ Med Sci, Dept Dermatol, 49 Przybyszewskiego St, PL-60355 Poznan, Poland

来源：

POSTEPY DERMATOLOGII I ALERGOLOGII | 2024年 / 41卷 / 02期

关键词：

afamelanotide; protoporphyria; erythropoietic porphyria; MELANOCYTE-STIMULATING HORMONE; ULTRAVIOLET-B PHOTOTHERAPY; ERYTHROPOIETIC PROTOPORPHYRIA; ALPHA-MELANOTROPIN; GENE VARIANTS; BETA-CAROTENE; ANALOG; PIGMENTATION; VITILIGO; EFFICACY;

D O I：

10.5114/ada.2024.138818

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Afamelanotide is a synthetic alpha melanocyte stimulating hormone presenting a higher activity than natural hormones. Its main properties are related to the enhanced production of eumelanin by agonistically binding to the melanocortin-1 receptor. Since 2016 afamelanotide has been especially applied to treat cases of erythropoietic porphyria (EPP), where painful photosensitivity has been observed since early childhood. The positive effect of af - amelanotide in EPP administered subcutaneously improved tolerance to artificial white light and increased pain -free time spent in direct sunlight. In this review we summarize the possible use of afamelanotide in dermatology, with special emphasis on EPP and encourage including afamelanotide as a treatment option in patient care.

引用

页码：149 / 154

页数：6

共 50 条

[1] Afamelanotide: A Review in Erythropoietic Protoporphyria
Esther S. Kim
Karly P. Garnock-Jones
American Journal of Clinical Dermatology, 2016, 17 : 179 - 185
[2] Afamelanotide: A Review in Erythropoietic Protoporphyria
Kim, Esther S.
Garnock-Jones, Karly P.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2016, 17 (02) : 179 - 185
[3] Afamelanotide for Erythropoietic Protoporphyria
Langendonk, J. G.
Balwani, M.
Anderson, K. E.
Bonkovsky, H. L.
Anstey, A. V.
Bissell, D. M.
Bloomer, J.
Edwards, C.
Neumann, N. J.
Parker, C.
Phillips, J. D.
Lim, H. W.
Hamzavi, I.
Deybach, J. -C.
Kauppinen, R.
Rhodes, L. E.
Frank, J.
Murphy, G. M.
Karstens, F. P. J.
Sijbrands, E. J. G.
de Rooij, F. W. M.
Lebwohl, M.
Naik, H.
Goding, C. R.
Wilson, J. H. P.
Desnick, R. J.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (01): : 48 - 59
[4] Afamelanotide for the treatment of erythropoietic protoporphyria
Minder, Elisabeth Irene
EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (04): : 341 - 349
[5] Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
Wensink, Debby
Wagenmakers, Margreet A. E. M.
Langendonk, Janneke G.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (02) : 151 - 160
[6] Advances in the management of erythropoietic protoporphyria - role of afamelanotide
Lane, Ashley M.
McKay, Jerome T.
Bonkovsky, Herbert L.
APPLICATION OF CLINICAL GENETICS, 2016, 9 : 179 - 189
[7] Erythropoietic protoporphyria and afamelanotide: a patient's perspective
O'Reilly, Marese
Mcguire, Vicky A.
Dawe, Robert S.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (02) : 186 - 187
[8] CAROTENOIDS IN ERYTHROPOIETIC PROTOPORPHYRIA AND OTHER PHOTOSENSITIVITY DISEASES
MATHEWSROTH, MM
CAROTENOIDS IN HUMAN HEALTH, 1993, 691 : 127 - 138
[9] Cutaneous effects of α-MSH-analogue afamelanotide in treatment of erythropoietic protoporphyria
Strunk, T.
Hetzer, S.
Kochs, C.
Muehlenstaedt, E.
Siegesmund, M.
Kuerten, V.
Poblete-Gutirrez, P.
Anstey, A.
Frank, J.
Neumann, N.
Hanneken, S.
EXPERIMENTAL DERMATOLOGY, 2012, 21 (03) : e13 - e14
[10] Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice
Wensink, Debby
Wagenmakers, Margreet A. E. M.
Barman-Aksozen, Jasmin
Friesema, Edith C. H.
Wilson, J. H. Paul
van Rosmalen, Joost
Langendonk, Janneke G.
JAMA DERMATOLOGY, 2020, 156 (05) : 570 - 575

← 1 2 3 4 5 →